SCHEMBL24920520

SCHEMBL24920520

COCc1ccnc(N2CCCCC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.46
▸ AOC3 Q16853 2/20 0.43
▸ ACHE P22303 4/20 0.43
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ RAB9A P51151 1/20 0.39
▸ CCNT1 O60563 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ RXRA P19793 1/20 0.38
▸ GRIN1 Q05586 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24921040 0.98 AOC3 (0.44) MAPTAOC3ACHEKMT2AMEN1
SCHEMBL24921023 0.95 AOC3 (0.44) MAPTAOC3ACHEKMT2ACA12
SCHEMBL24920536 0.86 ACHE (0.48) AOC3ACHEKMT2AMEN1HTT
SCHEMBL24920548 0.86 ACHE (0.48) AOC3ACHEKMT2AMEN1CA12
SCHEMBL24920523 0.85 ADRB1 (0.51) AOC3ACHEHPGD
SCHEMBL15599258 0.82 ACHE (0.46) ACHECA12CA1CA2CA9
SCHEMBL21715629 0.80 ACHE (0.47) MAPTACHEKMT2AMEN1CCNT1
SCHEMBL24921022 0.80 AOC3 (0.38) AOC3ACHERXRAGRIN1GRIN2B
SCHEMBL24921790 0.79 AOC3 (0.39) AOC3ACHERXRAGRIN1GRIN2B
SCHEMBL24921025 0.79 RXRA (0.39) AOC3RXRAGRIN1GRIN2BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 — — WO disclosed
Send feedback